Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

PDC Healthcare Introduces New Line of Spee-D-Mark™ 3D Breast Tomosynthesis Markers for Mammography


Posted on: 31 Oct 17

VALENCIA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- PDC Healthcare, a global leader of innovative identification and patient safety solutions, announced today the release of its new line of Spee-D-Mark™ 3D Breast Tomosynthesis Markers for mammography.  Specifically designed for 3D Digital Breast Tomosynthesis (DBT), Spee-D-Mark™ 3D Markers help technologists and radiologists mark and identify moles, scars, palpable masses, and areas of concern with minimal “slinky” artifact for 3D mammograms.  Since 1995, PDC Healthcare has provided Spee-D-Mark™ Skin Markers under the St. John Companies brand, offering high quality markers at affordable prices.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9650066e-0073-4219-9538-f8cd69ffdf67.

The use of breast tomosynthesis, also referred to as 3D mammography, has been steadily increasing over the past decade as it has been found to be more effective in the detection of breast cancer, particularly in women with complex dense breast tissue.  Studies show that approximately 43% of US women ages 40 to 74 years old are classified as having dense breasts, and women with dense breasts may be 6 times more likely to develop breast cancer. A study published by the Journal of Clinical Oncology revealed that adding 3D Digital Tomosynthesis to regular screenings can detect more cancers in dense breasts than standard 2D imaging.

Spee-D-Mark™ 3D Breast Tomo Markers are PDC Healthcare’s new line of skin markers that provide imaging centers and hospitals with a high-quality marking solution at an affordable price to accommodate the growing adoption of 3D DBT.  Four new Spee-D-Mark™ products are being offered, including, mole markers, scar markers, markers for non-palpable areas of concern, and markers for palpable masses.  Compatible with 2D and 3D mammography, PDC Healthcare’s skin markers offer an added convenience so that one marker can be used for both.  Spee-D-Mark™ low density markers are not only specially designed to show up clearly when “in slice,” and minimize the “slinky” artifact when they’re not in frame, but cost substantially less than the leading brand and are on most national GPO contracts as well.

“Now facilities and providers that offer breast tomosynthesis have more convenient and affordable options for 3D markers,” said Jen Whitcomb, Mammography Marketing Manager for PDC Healthcare.  “Providers can save time with one-stop shopping for mammography supplies.” 

Made of 100% lead-free and latex-free material, Spee-D-Mark™ 3D Breast Tomo Markers feature a branded teal and swirl pattern which is attractive and also easy to apply and remove.  Each marker is radiolucent when “in slice” to limit obscuring of breast tissue and barely there when “out of slice.”

About PDC Healthcare

With over 60 years of experience, PDC Healthcare connects people, products, and technology worldwide through innovative identification systems for the safe and efficient management of patients and procedures. PDC Healthcare is the result of the merger between two industry leaders and pioneers in healthcare: Precision Dynamics Corporation (PDC) and The St. John Companies Inc.

PDC Healthcare is a global leader and pacesetter in the development of wristband, label, medical records, and imaging systems. An originator of innovative technologies, the company introduced the first single-piece patient wristband, first bar code wristband system, first thermal printer wristband, first Smart Band® RFID wristband system, and the award-winning PDC Smart® Kiosk, among many other innovations.

PDC Healthcare products are used by over 90% of U.S. hospitals and comprise a comprehensive range of solutions that provide positive ID and positive clinical outcomes, while meeting important guidelines of The Joint Commission, World Healthcare Organization, FDA, AHA, and HIPAA. Complying with ISO 9001 standards, PDC Healthcare follows a systematic, world-standard approach to ensure superior product design, manufacturing, and customer support services. For more information, visit www.pdcorp.com or www.pdchealthcare.com

On Dec. 28, 2012, PDC Healthcare was acquired by Brady Corporation, (NYSE:BRC) a world leader in identification solutions for premises, products, and people.

Media Contact:
Jennifer Scinto
PDC Healthcare
661.257.0233 x1252
jennifer_scinto@pdcorp.com

GlobeNewswire
globenewswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.